全文获取类型
收费全文 | 51390篇 |
免费 | 5083篇 |
国内免费 | 2284篇 |
专业分类
耳鼻咽喉 | 852篇 |
儿科学 | 1187篇 |
妇产科学 | 468篇 |
基础医学 | 6598篇 |
口腔科学 | 7240篇 |
临床医学 | 5098篇 |
内科学 | 5079篇 |
皮肤病学 | 240篇 |
神经病学 | 1511篇 |
特种医学 | 2315篇 |
外国民族医学 | 22篇 |
外科学 | 10348篇 |
综合类 | 7392篇 |
现状与发展 | 9篇 |
预防医学 | 1987篇 |
眼科学 | 208篇 |
药学 | 2821篇 |
35篇 | |
中国医学 | 1644篇 |
肿瘤学 | 3703篇 |
出版年
2024年 | 78篇 |
2023年 | 765篇 |
2022年 | 1012篇 |
2021年 | 1991篇 |
2020年 | 2037篇 |
2019年 | 1855篇 |
2018年 | 1675篇 |
2017年 | 1866篇 |
2016年 | 1886篇 |
2015年 | 2048篇 |
2014年 | 3403篇 |
2013年 | 4497篇 |
2012年 | 2699篇 |
2011年 | 3173篇 |
2010年 | 2707篇 |
2009年 | 2573篇 |
2008年 | 2494篇 |
2007年 | 2519篇 |
2006年 | 2229篇 |
2005年 | 2105篇 |
2004年 | 1844篇 |
2003年 | 1657篇 |
2002年 | 1398篇 |
2001年 | 1235篇 |
2000年 | 1022篇 |
1999年 | 908篇 |
1998年 | 777篇 |
1997年 | 729篇 |
1996年 | 694篇 |
1995年 | 518篇 |
1994年 | 531篇 |
1993年 | 387篇 |
1992年 | 392篇 |
1991年 | 325篇 |
1990年 | 276篇 |
1989年 | 263篇 |
1988年 | 221篇 |
1987年 | 198篇 |
1986年 | 184篇 |
1985年 | 227篇 |
1984年 | 183篇 |
1983年 | 162篇 |
1982年 | 188篇 |
1981年 | 137篇 |
1980年 | 130篇 |
1979年 | 117篇 |
1978年 | 129篇 |
1977年 | 85篇 |
1976年 | 77篇 |
1975年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
81.
Monolayer cultures of normal human bone cells contain multiple subpopulations of alkaline phosphatase positive cells 总被引:5,自引:0,他引:5
Toshikatsu Matsuyama K. -H. William Lau Jon E. Wergedal 《Calcified tissue international》1990,47(5):276-283
Summary Cytochemical staining of normal human bone cells in monolayer cultures for alkaline phosphatase (ALP) indicated that the cultures
contained mixed-cell populations. Time course evaluations of the cytochemical staining revealed, in addition to the ALP-negative
cell population, at least two subpopulations of ALP-positive human bone cells with different levels of ALP. A cytochemical
method has been developed which separates the ALP-positive cells into high and intermediate ALP subpopulations. In this method,
human bone cells were stained for ALP using an azo-dye method and incubating at 4°C for 10 and 30 minutes, respectively. We
defined the cell population that stained positively for ALP at 10 minutes as strong ALP-positive cells, and both strong and
intermediate cells were stained at 30 minutes. The intermediate cells were determined from the difference between the values
at the two time points. The intra- and interassay variations of the assay, with the same investigator in blinded investigations,
were both less than 10% and the interobserver variation was approximately 25%. Analysis of the distribution of ALP levels
in cells with a laser densitometer confirmed the presence of at least three cell subpopulations. 1,25(OH)2D3 treatment increased the proportions of both ALP-positive cell populations, whereas TGF-beta treatment increased only the
intermediate ALP-positive cell population. On the contrary, fluoride increased the proportion of the strong ALP cells, and
IGF-1 had no effect on the proportions of either ALP-positive subpopulation. When the ALP-specific activity was compared with
the percentage of each ALP-positive subpopulations for the cells treated with effectors, the ALP-specific activity correlated
with the total ALP-positive and with the strong ALP-positive populations but not with the intermediate ALP-positive subpopulation.
In summary, this study represents the first evidence that normal human bone cells in monolayer cultures contained at least
two subpopulations of ALP-positive cells, and that bone cell effectors could have differential effects on each cell population. 相似文献
82.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
83.
Fumihiko Iwaku 《Journal of bone and mineral metabolism》1989,7(1):7-11
The three dimensional vascular microarchitecture of mercox resin on the lateral surface of parietal bone in Wistar strain
adult male rats (b. w. 260–350 g.) was studied in relation to bone formation by SEM observation of corrosion casts.
The microarchitecture was a single layer of network composed of precapillary artery, capillary and postcapillary vein, which
were serpigious, sometimes joined with the vein from the vascular foramen of bone. The meshes of this network, which were
irregular and varied in size, existed apart from the bone surface.
According to the report of Iwaku and Ozawa (1986), it was reported that the vascular microarchitecture of the bone surface
was very changable during the process of bone remodeling and this network, which was shown on the flat bone surface in this
study, was very similar to one in the resting phase and/or the period in which the bone formation further advanced.
From these facts and the morphological features of the bone surface observed here by SEM, it is suggested that this vascular
network was closely related with the resting stage and/or the period in which bone formation further advanced in bone remodeling. 相似文献
84.
本研究从1kg牛长骨中提取出部分纯化的牛骨形态发生蛋白(bBMP)160mg.电泳显示其主要区带分子量在33.7~13.4ku(34.0~13.5kd)之间,包括bBMP的生物活性成份18.1ku(18.2kd)蛋白质。将bBMP植入NIH小鼠肌肉内,5天诱导出软骨细胞,10天形成骨组织,14天出现骨髓。软骨或骨的诱发率87.5%。作者观察到bBMP诱导成骨的方式是软骨内成骨,其过程可分为间质细胞增生期、软骨细胞演变期和骨形成期。 相似文献
85.
目的 :研究老年人不同疾病时骨密度 (BMD)的分布情况。方法 :用DXADAS 6 0 0EX型骨密度仪对183例老年患者进行左侧远程桡骨加尺骨BMD检测。结果 :内分泌疾病组、消化道疾病组和其它疾病组的患病率分别为 72 7% ,2 0 6 %和 31 4 %。T值比较 :三组差异明显 (P <0 0 0 1)。累积骨丢失率 (ABLR)比较 :前一组明显高于后两组病人 (P <0 0 1)。BMD比较中 ,内分泌和其它疾病组明显低于消化道疾病组 (P <0 0 0 1)。相关分析显示 ,内分泌和消化道疾病组的年龄变化与BMD呈正相关 (r =0 5 19P <0 0 0 1和r =0 5 89P <0 0 0 1) ,内分泌疾病组和其它疾病组的体重变化与BMD呈正相关 (r=0 918P <0 0 0 1和r =0 338P <0 0 0 1)。结论 :老年人骨质疏松 (OP)患病率以内分泌疾病组最高 ,消化道疾病组较低 ;随年龄和体重增加 ,BMD降低加重。 相似文献
86.
目的:了解温州地区人群不同年龄组骨质疏松患病率及同年龄组男女骨质疏松患病的差异,强调早期预防治疗老年人及绝经期妇女骨质疏松的重要性,方法:应用单能量X线(SXA)骨密度仪测量246例正常人的右跟骨骨密度,结果:男性大于60岁组较小于60岁组骨密度(BMD)降低明显(P<0.05);女性50岁以上组与小于50岁组相比,BMD下降差异有极显性(P<0.01);各年龄组男女相比,男性BMD明显高于女性(P<0.05)。结论:女性骨质疏松症的发病大多以绝经后为主,雌激素在维持骨量方面具有重要的作用。SXA检测的跟骨含95%小梁骨,能较好地确定骨质疏松的风险水平,且其具有价廉、简便,快捷,较准确等特点,故不失为一种较好的临床筛查手段。 相似文献
87.
Platelet factor 4 ( PF4) is a negativehematopoietic factor.It can inhibit the prolifera-tion of endothelial cells and hematopoietic stem/progenitor cells,particularly megakaryoryocyticcells,reversibly[1] ,inhibit DNA synthesis,blockcell cycle progression during S phase and reducethe sensibility of normal hematopoietic stem/pro-genitor cells,but not some cancer or leukemia celllines,to cytotoxic drugs and ionizing radia-tion[2 - 3] ,and it also can cause a population in-crease of the stem cel… 相似文献
88.
[目的]结合文献探讨骨旁脂肪瘤的命名、病因、临床病理表现和影像学特点。[方法]将国内文献的20例一起列入临床资料分析,包括作者14例共34例术前均行X线摄片,18例行CT检查,4例行MRI检查。[结果]本病发生于任何年龄,成人多见,以四肢长管状骨为好发,其次发生于扁平骨(骨盆、肩岬骨、髌骨、肋骨)、不规则骨(胸椎、腰椎、骶尾椎)、短管状骨和跗骨;本病临床误诊率为41.17%,X线误诊率26.47%,CT及MRI诊断率100%;34例均手术切除,病理报告为脂肪瘤,3例低度恶变;随访2~10年,仅1例复发并恶变。[结论]骨旁脂肪瘤是最佳的命名,病因未明,但与遗传和先天因素及创伤和炎症因素有关;病理表现为带骨蒂的脂肪瘤,细胞学形态为脂肪组织;影像学具有特征性表现。 相似文献
89.
目的 探讨齿槽裂修复治疗的目的、方法以及治疗时机的选择。方法 查阅1950年至2006年有关齿槽裂修复的文献,归纳文献中报道的不同方法,并评价其各自的优缺点。结果 齿槽裂修复的主要目的:关闭口鼻瘘;建立稳定、连续的上颌骨牙弓;为牙齿萌出提供基础;为上唇和鼻底提供稳定支架。主要治疗方法:植骨术;牵引成骨技术;组织工程骨和生长因子应用;引导骨再生技术。患者最佳的手术治疗时机是9~11岁时混合牙列期。结论 在9~11岁混合牙列期手术,以髂骨松质骨为移植材料被认为是修复齿槽裂的主要手段。牵引成骨技术、组织工程技术和引导骨再生技术,将是齿槽裂修复的新方向。 相似文献
90.